Selected article for: "active site and docking study"
Author: Alexpandi, Rajaiah; De Mesquita, Joelma Freire; Pandian, Shunmugiah Karutha; Ravi, Arumugam Veera
Title: Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis
  • Cord-id: kbmiysnq
  • Document date: 2020_7_23
    • ID: kbmiysnq
    Snippet: The novel coronavirus SARS-CoV-2 disease “COVID-19” emerged in China and rapidly spread to other countries; due to its rapid worldwide spread, the WHO has declared this as a global emergency. As there is no specific treatment prescribed to treat COVID-19, the seeking of suitable therapeutics among existing drugs seems valuable. The structure availability of coronavirus macromolecules has encouraged the finding of conceivable anti-SARS-CoV-2 therapeutics through in silico analysis. The result
    Document: The novel coronavirus SARS-CoV-2 disease “COVID-19” emerged in China and rapidly spread to other countries; due to its rapid worldwide spread, the WHO has declared this as a global emergency. As there is no specific treatment prescribed to treat COVID-19, the seeking of suitable therapeutics among existing drugs seems valuable. The structure availability of coronavirus macromolecules has encouraged the finding of conceivable anti-SARS-CoV-2 therapeutics through in silico analysis. The results reveal that quinoline,1,2,3,4-tetrahydro-1-[(2-phenylcyclopropyl)sulfonyl]-trans-(8CI) and saquinavir strongly interact with the active site (Cys-His catalytic dyad), thereby are predicted to hinder the activity of SARS-CoV-2 3CLpro. Out of 113 quinoline-drugs, elvitegravir and oxolinic acid are able to interact with the NTP entry-channel and thus interfere with the RNA-directed 5′-3′ polymerase activity of SARS-CoV-2 RdRp. The bioactivity-prediction results also validate the outcome of the docking study. Moreover, as SARS-CoV-2 Spike-glycoprotein uses human ACE2-receptor for viral entry, targeting the Spike-RBD-ACE2 has been viewed as a promising strategy to control the infection. The result shows rilapladib is the only quinoline that can interrupt the Spike-RBD-ACE2 complex. In conclusion, owing to their ability to target functional macromolecules of SARS-CoV-2, along with positive ADMET properties, quinoline,1,2,3,4-tetrahydro-1-[(2-phenylcyclopropyl)sulfonyl]-trans-(8CI), saquinavir, elvitegravir, oxolinic acid, and rilapladib are suggested for the treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • absorption analysis and acute respiratory syndrome: 1, 2, 3, 4
    • absorption analysis and acute syndrome: 1, 2, 3, 4
    • absorption analysis and acute toxicity: 1
    • absorption analysis and admet analysis: 1, 2, 3, 4, 5, 6
    • absorption analysis and admet toxicity excretion metabolism distribution: 1, 2, 3, 4, 5, 6
    • absorption analysis and admet toxicity excretion metabolism distribution absorption: 1, 2, 3, 4, 5, 6
    • active domain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • active domain and acute syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute toxicity: 1
    • active site and admet analysis: 1, 2, 3, 4, 5, 6
    • active site and admet toxicity excretion metabolism distribution: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active site and admet toxicity excretion metabolism distribution absorption: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active site and logp value: 1
    • acute respiratory syndrome and admet property: 1, 2
    • acute respiratory syndrome and admet toxicity excretion metabolism distribution: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and admet toxicity excretion metabolism distribution absorption: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and administer dose: 1